Sucampo Pharmaceuticals, Inc. (SCMP) Tops Q2 EPS by 1c; Updates FY14 GAAP EPS Outlook

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $24.1 million versus the consensus estimate of $24.06 million.

Sucampo Pharmaceuticals, Inc. sees FY2014 EPS of $0.08-$0.13, versus the consensus of $0.18.

For earnings history and earnings-related data on Sucampo Pharmaceuticals, Inc. (SCMP) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Alabama Power Co. 5.875% Sr. Notes Series 2007b (ALM) Tops Q2 EPS by 62c
• Borr Drilling (BORR) Misses Q2 EPS by 69c